Guillermo J Ruiz-ArgÃ¼elles

List of Publications by Year
in descending order

179 papers	2,717 citations	218677 26 h-index	302126 39 g-index
185 all docs	185 docs citations	185 times ranked	2224 citing authors

#	Article	IF	Citations
1	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, 2013, 121, 1935-1943.	1.4	96
2	Leukaemia and nutrition I: Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia. Leukemia Research, 1989, 13, 899-906.	0.8	94
3	Alemtuzumab for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2008, 14, 10-15.	2.0	72
4	Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. American Journal of Hematology, 2001, 66, 241-244.	4.1	70
5	Dimethyl Sulfoxide-Induced Toxicity in Cord Blood Stem Cell Transplantation: Report of Three Cases and Review of the Literature. Acta Haematologica, 2009, 122, 1-5.	1.4	69
6	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Annals of Hematology, 2014, 93, 2001-2010.	1.8	58
7	Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplantation, 2000, 25, 131-133.	2.4	57
8	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biology of Blood and Marrow Transplantation, 2003, 9, 157-161.	2.0	51
9	Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?. Bone Marrow Transplantation, 2008, 42, 23-28.	2.4	47
10	Red cell indices in normal adults residing at altitudes from sea level to 2670 meters. American Journal of Hematology, 1980, 8, 265-271.	4.1	46
11	A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplantation, 2009, 44, 715-719.	2.4	44
12	Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican experience. American Journal of Hematology, 2006, 81, 157-161.	4.1	42
13	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biology of Blood and Marrow Transplantation, 2003, 9, 157-161.	2.0	41
14	A critical review of the prognostic value of the nutritional status at diagnosis in the outcome of therapy of children with acute lymphoblastic leukemia. Revista De Investigacion Clinica, 2003, 55, 31-5.	0.4	41
15	Filgrastimâ€mobilized peripheralâ€blood stem cells can be stored at 4 degrees and used in autografts to rescue highâ€dose chemotherapy. American Journal of Hematology, 1995, 48, 100-103.	4.1	40
16	The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplantation, 2005, 36, 1043-1047.	2.4	39
17	Results of an Autologous Noncryopreserved, Unmanipulated Peripheral Blood Hematopoietic Stem Cell Transplant Program: A Single-Institution, 10-Year Experience. Acta Haematologica, 2003, 110, 179-183.	1.4	38
18	Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. Hematology, 2007, 12, 387-391.	1.5	36

#	Article	IF	Citations
19	Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos. American Journal of Hematology, 2001, 66, 28-31.	4.1	34
20	More on Geographic Hematology: The Breakpoint Cluster Regions of the PML/RARÎ± Fusion Gene in Mexican Mestizo Patients with Promyelocytic Leukemia are Different from Those in Caucasians. Leukemia and Lymphoma, 2004, 45, 1365-1368.	1.3	33
21	Sticky Platelet Syndrome: History and Future Perspectives. Seminars in Thrombosis and Hemostasis, 2014, 40, 526-534.	2.7	32
22	Importance of Nutrition in the Treatment of Leukemia in Children and Adolescents. Archives of Medical Research, 2016, 47, 585-592.	3.3	32
23	Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basis. , 1998, 58, 161-164.		31
24	Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial. American Journal of Hematology, 2005, 78, 21-26.	4.1	31
25	Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. , 1998, 78, 52-55.		30
26	Donor cell leukemia: A critical review. Leukemia and Lymphoma, 2007, 48, 25-38.	1.3	30
27	Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplantation, 2007, 40, 535-539.	2.4	29
28	Observational study of multiple myeloma in Latin America. Annals of Hematology, 2017, 96, 65-72.	1.8	29
29	Metabolomic profile of insulin resistance in patients with multiple sclerosis is associated to the severity of the disease. Multiple Sclerosis and Related Disorders, 2018, 25, 316-321.	2.0	29
30	Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. International Journal of Hematology, 2002, 76, 376-379.	1.6	28
31	Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning in Patients with Acute Myelogenous Leukemia Eligible for Conventional Allografting: A Prospective Study. Leukemia and Lymphoma, 2004, 45, 1191-1195.	1.3	28
32	Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. European Journal of Haematology, 1995, 54, 18-20.	2.2	28
33	Acute Leukemia Characteristics are Different Around the World: the Mexican Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 46-51.	0.4	28
34	Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transplantation, 2018, 53, 457-460.	2.4	28
35	A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells. Acta Haematologica, 2017, 137, 214-219.	1.4	27
36	Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Annals of Hematology, 2010, 89, 299-303.	1.8	25

#	Article	IF	Citations
37	Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplantation, 2007, 40, 119-123.	2.4	24
38	Diagnosing and treating mixed phenotype acute leukemia: a multicenter 10-year experience in MÃ©xico. Annals of Hematology, 2014, 93, 595-601.	1.8	24
39	Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia. Hematology, 2007, 12, 255-256.	1.5	23
40	Non-Cryopreserved Unmanipulated Hematopoietic Peripheral Blood Stem Cell Autotransplant Program. Archives of Medical Research, 1999, 30, 380-384.	3.3	22
41	Multiple Myeloma in Mexico: A 20-year experience at a single institution. Archives of Medical Research, 2004, 35, 163-167.	3.3	22
42	Donor cell leukemia after non-myeloablative allogeneic stem cell transplantation: A single institution experience. Leukemia and Lymphoma, 2006, 47, 1952-1955.	1.3	22
43	A Mexican way to cope with stem cell grafting. Hematology, 2012, 17, s195-s197.	1.5	22
44	Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica, 2002, 87, 894-6.	3.5	22
45	Primary Thrombophilia in Mexico III: A Prospective Study of the Sticky Platelet Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 273-277.	1.7	20
46	Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience. Leukemia and Lymphoma, 2011, 52, 314-316.	1.3	20
47	Primary Thrombophilia in MÃ©xico X. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 91-95.	1.7	18
48	Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clinical Endocrinology, 2001, 54, 731-738.	2.4	17
49	Alemtuzumab-Induced Resolution of Refractory Cutaneous Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2008, 14, 7-9.	2.0	17
50	Primary thrombophilia in Mexico: A prospective study. , 1999, 60, 1-5.		16
51	Hairy cell leukemia is infrequent in MÃ©xico and has a geographic distribution. , 1996, 52, 316-318.		15
52	Follow up of Hemopoietic Chimerism in Individuals Given Allogeneic Hemopoietic Stem Cell Allografts Using an Immunosuppressive, Non-myeloablative Conditioning Regimen: a Prospective Study in a Single Institution. Leukemia and Lymphoma, 2002, 43, 1509-1511.	1.3	15
53	Breaking dogmata to help patients: non-myeloablative haematopoietic stem cell transplantation. Expert Opinion on Biological Therapy, 2004, 4, 1693-1699.	3.1	15
54	Primary thrombophilia in Mexico IX. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 689-692.	1.7	15

#	Article	IF	Citations
55	Nonalcoholic Fatty Liver Disease May Cause Thrombocytopenia. Acta Haematologica, 2014, 132, 159-162.	1.4	15
56	The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-MÃ©xico Program: A Myriad of Experiences and Knowledge. Frontiers in Neurology, 2021, 12, 647425.	2.4	15
57	Studies on lymphomata. III. Lymphomata, granulomata and tuberculosis. Cancer, 1983, 52, 258-262.	4.1	14
58	Lymphocyte subsets in patients with aplastic anemia. American Journal of Hematology, 1984, 16, 267-275.	4.1	14
59	Extramedullary Leukemic Relapses following Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning. International Journal of Hematology, 2005, 82, 262-265.	1.6	14
60	Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. Bone Marrow Transplantation, 2005, 36, 715-720.	2.4	14
61	Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting. Lancet Haematology,the, 2020, 7, e509-e510.	4.6	14
62	Features of the Engraftment of Allogeneic Hematopoietic Stem Cells Using Reduced-Intensity Conditioning Regimens. Leukemia and Lymphoma, 2001, 42, 145-150.	1.3	13
63	Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. Annals of Hematology, 2007, 86, 277-282.	1.8	13
64	Whither the bone marrow transplant?. Hematology, 2010, 15, 1-3.	1.5	13
65	Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. European Journal of Haematology, 2011, 87, 521-530.	2.2	13
66	The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Hematology/ Oncology and Stem Cell Therapy, 2015, 8, 16-21.	0.9	13
67	Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center. Clinical and Experimental Immunology, 2019, 198, 351-358.	2.6	13
68	Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e43-e50.	0.4	13
69	Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries. JCO Global Oncology, 2021, 7, 577-584.	1.8	13
70	Long-Term Results of the Immunosuppressive Treatment of Patients with Severe Acquired Aplastic Anemia: A Single Institution Study. Acta Haematologica, 2003, 110, 184-187.	1.4	12
71	Haematopoietic stem cell transplantation to treat aplastic anaemia. Expert Opinion on Biological Therapy, 2005, 5, 617-626.	3.1	12
72	CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value. Hematology, 2012, 17, 66-70.	1.5	12

#	Article	IF	Citations
73	Antibodies in the Treatment of Aplastic Anemia. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 99-106.	2.3	12
74	Primary thrombophilia in MÃ©xico XII: Miscarriages are more frequent in persons with the Sticky Platelet Syndrome (SPS). Turkish Journal of Haematology, 2017, 34, 239-243.	0.5	12
75	No Cytomegalovirus-related Deaths After Non-ablative Stem Cell Allografts. Hematology, 2002, 7, 95-99.	1.5	11
76	Decreased Transfusion Requirements in Patients Given Stem Cell Allografts Using a Non-myeloablative Conditioning Regimen: A Single Institution Experience. Hematology, 2003, 8, 151-154.	1.5	11
77	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance. Mayo Clinic Proceedings, 2008, 83, 601-602.	3.0	11
78	The sticky platelet syndrome. Hematology, 2013, 18, 230-232.	1.5	11
79	The treatment of CML at an environment with limited resources. Hematology, 2016, 21, 576-582.	1.5	11
80	Geographic Hematology: Some Observations in Mexico. Acta Haematologica, 2018, 140, 114-120.	1.4	11
81	WaldenstrÃ¶m's macroglobulinemia is infrequent in Mexican Mestizos: experience of a hematological diseases referral center. Revista De Investigacion Clinica, 2000, 52, 497-9.	0.4	11
82	Low Doses of High-Potency Antithymocyte Globulin (ATG) in Severe Aplastic Anemia: Experience with the Mexican ATG. Acta Haematologica, 1989, 81, 70-74.	1.4	10
83	Umbilical cord blood transplantation using non-myeloablative conditioning: The Mexican experience. Hematology, 2006, 11, 355-359.	1.5	10
84	Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology, 2007, 12, 193-197.	1.5	10
85	Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Annals of Hematology, 2010, 89, 1045-1052.	1.8	10
86	Haploidentical Bone Marrow Transplantation in 2015 and Beyond. Current Oncology Reports, 2015, 17, 57.	4.0	10
87	The big freeze may be over: a contracting universe for cryopreservation?. Bone Marrow Transplantation, 2018, 53, 947-948.	2.4	10
88	The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. American Journal of Hematology, 2004, 75, 200-204.	4.1	9
89	The Mexican approach to conduct allogeneic stem cell transplantation: Braking dogmata and facing the Matthew effect. Hematology, 2005, 10, 154-160.	1.5	9
90	Primary thrombophilia in MÃ©xico VII: the V617F mutation of JAK2 is not a frequent cause of thrombosis. Hematology, 2008, 13, 244-246.	1.5	9

#	Article	IF	Citations
91	Treatment of hairy cell leukemia: long-term results in a developing country. Hematology, 2012, 17, 140-143.	1.5	9
92	Publications of bone marrow transplants in Latin America. A report of the Latin American Group of Bone Marrow Transplantation. Bone Marrow Transplantation, 2015, 50, 1130-1131.	2.4	9
93	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Annals of Hematology, 2019, 98, 941-949.	1.8	9
94	Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution. Acta Haematologica, 2020, 143, 552-558.	1.4	9
95	Chronic lymphocytic leukemia is infrequent in Mexican mestizos. International Journal of Hematology, 1999, 69, 253-5.	1.6	9
96	The Mexican Approach to Conduct Nonmyeloablative Stem Cell Transplantation Should Not Be Overlooked. International Journal of Hematology, 2003, 77, 526-527.	1.6	8
97	Successful Allogeneic Stem Cell Transplantation with Nonmyeloablative Conditioning in Patients with Relapsed Hodgkin's Disease Following Autologous Stem Cell Transplantation. Archives of Medical Research, 2003, 34, 242-245.	3.3	8
98	Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. American Journal of Hematology, 2007, 82, 400-402.	4.1	8
99	Staunching the rising costs of haematological health care. Lancet Haematology,the, 2016, 3, e455.	4.6	8
100	Primary Thrombophilia XIV: Worldwide Identification of Sticky Platelet Syndrome. Seminars in Thrombosis and Hemostasis, 2019, 45, 423-428.	2.7	8
101	An Addition to Geographic Hematology: Chronic Myeloproliferative Diseases Are Infrequent in Mexican Mestizos. International Journal of Hematology, 2002, 75, 499-502.	1.6	7
102	Altered Functional Status of the Hypothalamic Dopaminergic Tone in Patients with Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Study. Biology of Blood and Marrow Transplantation, 2006, 12, 566-572.	2.0	7
103	t(8;21) (q22;q22) Acute myelogenous leukemia in MÃ©xico: A single institution experience. Hematology, 2006, 11, 235-238.	1.5	7
104	Romiplostin may revert the thrombocytopenia in graftâ€versusâ€host disease. Hematology, 2011, 16, 108-109.	1.5	7
105	Long-term results of placental blood allografting using reduced-intensity conditioning: multicenter experience in a developing country. Hematology, 2011, 16, 155-159.	1.5	7
106	Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab. Hematology, 2013, 18, 175-177.	1.5	7
107	Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Expert Review of Hematology, 2017, 10, 809-819.	2.2	7
108	Determine safety of outpatient chemotherapy and autotransplants using refrigerated, nonâ€frozen grafts in persons with multiple sclerosis. Clinical Transplantation, 2019, 33, e13567.	1.6	7

#	Article	IF	Citations
109	Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988869.	1.7	7
110	Cell-Freezing Devices Are Not Strictly Needed to Start an Autologous Hematopoietic Transplantation Program: Non-Cryopreserved Peripheral Blood Stem Cells Can be Used to Restore Hematopoiesis after High Dose Chemotherapy: A Multicenter Experience in 268 Autografts in Patients with Multiple Myeloma or Lymphoma. Study on Behalf of the Latin-American Bone Marrow Transplantation Group (LABMT). Blood, 2014, 124, 849-849.	1.4	7
111	Minimal Residual Disease Testing in Acute Leukemia by Flow Cytometry Immunophenotyping: Prognostic Significance. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2007, 13, 22-26.	1.2	7
112	Analysis of HFE-Codon 63/282 (H63D/C282Y) Gene Variants in Mexican Mestizos. Archives of Medical Research, 2000, 31, 422-424.	3.3	6
113	Nephrotic syndrome after non-myeloablative stem cell transplantation. British Journal of Haematology, 2006, 132, 801-801.	2.5	6
114	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance. Mayo Clinic Proceedings, 2008, 83, 601-602.	3.0	6
115	The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience. Hematology, 2010, 15, 378-381.	1.5	6
116	Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkinâ€™s lymphoma in a developing country?. Hematology, 2012, 17, 193-197.	1.5	6
117	Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. American Journal of Hematology, 2012, 87, 941-941.	4.1	6
118	Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction. Hematology, 2014, 19, 435-440.	1.5	6
119	Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience. Hematology, 2015, 20, 263-266.	1.5	6
120	Stem Cell Transplantation Procedures Are Becoming Affordable for Individuals Living in Developing (Middle-Income) Countries. Acta Haematologica, 2016, 135, 79-80.	1.4	6
121	More on the thrombocytopenia of the non-alcoholic fatty liver disease. Hematology, 2017, 22, 316-319.	1.5	6
122	Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs?. Biology of Blood and Marrow Transplantation, 2017, 23, 1815-1816.	2.0	6
123	Glomerular Filtration Rate in Patients with Multiple Sclerosis Undergoing Stem Cell Transplantation and Treated with Cyclophosphamide. Laboratory Medicine, 2019, 50, 42-46.	1.2	6
124	Primary thrombophilia XV: antithrombotic treatment of sticky platelet syndrome worldwide. Annals of Blood, 2019, 4, 15-15.	0.4	6
125	Primary Thrombophilia in Mexico XIII: Localization of the Thrombotic Events in Mexican Mestizos With the Sticky Platelet Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961984170.	1.7	6
126	Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican Mestizo patients with chronic myelogenous leukemia. Revista De Investigacion Clinica, 2004, 56, 605-8.	0.4	6

#	Article	IF	Citations
127	Second allogeneic peripheral blood stem cell transplants with reduced-intensity conditioning. Revista De Investigacion Clinica, 2006, 58, 34-8.	0.4	6
128	Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation. Revista De Investigacion Clinica, 2016, 68, 181-3.	0.4	6
129	Outpatient allogeneic hematopoietic stem-cell transplantation: a review. Therapeutic Advances in Hematology, 2022, 13, 204062072210807.	2.5	6
130	â€˜The Mexican approachâ€™ to conduct NST. European Journal of Haematology, 2001, 67, 335-335.	2.2	5
131	Non-myeloablative bone marrow transplantation. Archives of Medical Research, 2003, 34, 554-557.	3.3	5
132	Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. Hematology, 2012, 17, 85-92.	1.5	5
133	Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings. Current Hematologic Malignancy Reports, 2021, 16, 40-44.	2.3	5
134	Non-alcoholic fatty liver disease and thrombocytopenia IV: its association with granulocytopenia. Hematology, Transfusion and Cell Therapy, 2022, 44, 491-496.	0.2	5
135	Advances in the diagnosis and treatment of acute and chronic leukemia in Mexico. Salud Publica De Mexico, 2016, 58, 291-295.	0.4	5
136	Gilbert's syndrome disclosed during the treatment of hematological malignancies. Hematology, 2005, 10, 59-60.	1.5	4
137	Autotransplantations Without Cryopreservation. Journal of Global Oncology, 2018, 4, 1-1.	0.5	4
138	Factors Involved in the Selection of Treatment in Patients with Hematological Malignancies. Acta Haematologica, 2019, 141, 54-54.	1.4	4
139	Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. Leukemia and Lymphoma, 2020, 61, 3112-3119.	1.3	4
140	Letter to the Editor: Bien plus Encore: Haplos Indeed Can be Completed on an Outpatient Basis. Transplantation and Cellular Therapy, 2021, 27, 519-520.	1.2	4
141	Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. International Journal of Cancer, 1998, 78, 52-55.	5.1	4
142	A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting. Blood Transfusion, 2009, 7, 127-31.	0.4	4
143	SIMPLIFICATION, NOT DEMYSTIFICATION NOR TRIVIALIZATION OF STEM CELL TRANSPLANTATION. Haematologica, 2001, 86, E07.	3.5	4
144	Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients. Revista De Investigacion Clinica, 2004, 56, 600-4.	0.4	4

#	Article	IF	Citations
145	High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma. Hematology, 2022, 27, 449-455.	1.5	4
146	Significance of one human leukocyte antigen mismatch on outcome of nonmyeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule. Bone Marrow Transplantation, 2005, 35, 335-339.	2.4	3
147	HFE-Codon 63/282 (H63D/C282Y) Gene Variants in Mexican Mestizos Are Not Risk Factors for Leukemia. Archives of Medical Research, 2006, 37, 65-67.	3.3	3
148	Re: Alemtuzumab-Induced Resolution of Pulmonary Noninfectious Complications in a Patient with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2008, 14, 1434-1435.	2.0	3
149	Donor-derived hairy cell leukemia. Leukemia and Lymphoma, 2009, 50, 1712-1714.	1.3	3
150	POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010016.	1.3	3
151	In pursuit of the graft-versus-myeloma effect: A single institution experience. Hematology, 2013, 18, 89-92.	1.5	3
152	Up to half of patients diagnosed with chronic lymphocytic leukemia in MÃ©xico may not require treatment. Hematology, 2020, 25, 156-159.	1.5	3
153	Long-term results of the treatment of Hodgkinâ€™s lymphoma in a resource-constrained setting: Real-world data from a single center. World Journal of Clinical Oncology, 2021, 12, 800-807.	2.3	3
154	Treatment of acute promyelocytic leukemia: a single institution experience. Revista De Investigacion Clinica, 2005, 57, 415-9.	0.4	3
155	Paroxysmal nocturnal hemoglobinuria in MÃ©xico: a 30-year, single institution experience. Revista De Investigacion Clinica, 2014, 66, 12-6.	0.4	3
156	Transient mixed chimerism after stem cell transplantation can induce durable molecular complete remissions in chronic myelogenous leukemia. Leukemia and Lymphoma, 2006, 47, 2590-2592.	1.3	2
157	Reduced-Intensity Allografting in Childhood Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2011, 17, 439-440.	2.0	2
158	On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS). International Journal of Hematology, 2012, 96, 144-145.	1.6	2
159	A New Breed in the Teaching of Medicine: Paid Lecturers, Trainers or Speakers?. Acta Haematologica, 2016, 135, 191-192.	1.4	2
160	Clearance of donor cell leukemia by means of graft versus leukemia effect: A case report. Hematology, 2016, 21, 470-473.	1.5	2
161	Modifications to the â€œClassicalâ€•Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Less Toxic Approach is Feasible and Improves the Neurological Condition. A Mexican Perspective. Biology of Blood and Marrow Transplantation, 2018, 24, S125-S126.	2.0	2
162	Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico. Archives of Medical Research, 2021, 52, 627-634.	3.3	2

#	Article	IF	Citations
163	Primary Thrombophilia XVI: A Look at the Genotype of the Sticky Platelet Syndrome Phenotype. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110442.	1.7	2
164	Assessment of residual disease in acute leukemia by means of polymerase chain reaction. Revista De Investigacion Clinica, 2000, 52, 118-24.	0.4	2
165	The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in MÃ©xico. Revista De Investigacion Clinica, 2006, 58, 458-61.	0.4	2
166	Core binding factor acute myeloid leukemia (CBF-AML) in MÃ©xico: a single institution experience. Revista De Investigacion Clinica, 2011, 63, 25-30.	0.4	2
167	Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances. Leukemia and Lymphoma, 2022, 63, 1236-1241.	1.3	2
168	miRNAs in multiple sclerosis: A clinical approach. Multiple Sclerosis and Related Disorders, 2022, 63, 103835.	2.0	2
169	Primary Thrombophilia XVII: A Narrative Review of Sticky Platelet Syndrome in MÃ©xico. Journal of Clinical Medicine, 2022, 11, 4100.	2.4	2
170	PML/RARÎ±(+) Hypergranular Acute Promyelocytic Leukemia (M3) Developing into an M3 Acute Myelocytic Leukemia without PML/RARÎ±. Acta Haematologica, 2000, 104, 124-127.	1.4	1
171	Molecular characterization of chronic myeloproliferative neoplasias in MÃ©xico. Hematology, 2009, 14, 261-265.	1.5	1
172	Iron deficiency anemia in low- and middle-income countries. Blood, 2013, 122, 2289-2289.	1.4	1
173	The Changing Pattern of Admission of Allograft Patients to the Intensive Care Unit. Acta Haematologica, 2016, 135, 70-71.	1.4	1
174	Primary Thrombophilia in MÃ©xico XI: Activated Protein C Resistance Phenotypes are Multifactorial. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 375-379.	0.6	1
175	A unique case of donor cell myeloma. Leukemia and Lymphoma, 2019, 60, 1839-1841.	1.3	1
176	DÃ©monstration de FaisabilitÃ©: Nonalcoholic Fatty Liver Disease May Cause Thrombocytopenia. Seminars in Thrombosis and Hemostasis, 2021, , .	2.7	1
177	Experience in developing countries. Pediatric Blood and Cancer, 2008, 50, 517-517.	1.5	0
178	Whither the Bone Marrow Transplantation in Multiple Myeloma?. Acta Haematologica, 2018, 139, 131-131.	1.4	0
179	Helicobacter pylori antibodies and multiple sclerosis: a single-center study and a short review of the literature. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	1.0	0